Sign in
Taking people in United StatesPhase 1/2

Dalfampridine with nerve stimulation and exercise after spinal cord injury

Tests dalfampridine plus stimulation and training in spinal cord injury.

Key facts

Who runs it
Shirley Ryan AbilityLab
Where
Chicago, United StatesSee the site
Trial code
Registry title
Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
Status
Recruiting
Phase
Phase 1/2
People taking part
27 people, planned
Started
1 Feb 2025
Expected to end
30 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Dalfampridine
  • Placebo
  • STDP stimulation
  • Exercise training
Record updated
3 June 2026

Who can take part

The trial is looking for adults with a spinal cord injury at least 6 months ago who can still slightly move ankle and hip muscles. It tests Dalfampridine (4-AP) twice a day with nerve stimulation and training.

Age
18-85 years
Sex
Men and women
Disease stage
Spinal cord injury 6 months after injury, at or above L2, ASIA A, B, C, or D, complete or incomplete. You must be able to make a small visible contraction of the muscles that lift the foot and bend the hip.
Earlier treatment
People taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, PR Interval prolonging drugs, or nervous system drugs that make seizures more likely cannot join.
Main reasons for not taking part
  • History of seizures or epilepsy, head injury, stroke, or a brain lesion
  • Any history of kidney problems
  • Pregnancy, or unsure of pregnancy and not wanting a pregnancy test
  • Ongoing cord compression, syrinx, or spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk
  • Metal plate in skull, scalp shrapnel, cochlear implants, or aneurysm clips
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Male and females between ages 18-85 years
  • SCI 6 months post injury
  • Spinal Cord injury at or above L2
  • ASIA A, B, C, or D, complete or incomplete
  • The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles

Who cannot take part

  • Any debilitating disease prior to the SCI that caused exercise intolerance
  • Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)
  • Individuals with scalp shrapnel, cochlear implants, or aneurysm clips
  • Individuals taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or PR Interval prolonging drugs
  • Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease
  • Any history of renal impairment
  • History of head injury or stroke
  • Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
  • History of seizures or epilepsy
  • Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk
  • If a women of child bearing age is unsure of the pregnancy, and does not want to take the pregnancy test
  • Premorbid, ongoing major depression or psychosis, altered cognitive status
  • Pregnant females
  • Metal plate in skull

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • SCI - spinal cord injury

This trial is currently available in United States.

  • Shirley Ryan AbilityLabChicago, United StatesContact: Monica Perez, PT, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.

The 2 groups in the trial

  • 4-AP(AM) + STDP stimulation + training + 4-AP(PM)Treatment being tested

    The effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of twice-daily-dosing 4-AP, STDP stimulation and training.

    Treatment: Dalfampridine, STDP stimulation, and Exercise training

  • Placebo(AM) + STDP stimulation + training + Placebo(PM)Placebo, for comparison

    The effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of twice-daily-dosing Placebo, STDP stimulation and training.

    Treatment: Placebo, STDP stimulation, and Exercise training

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Twice-daily Dosing 4-AP on Functional Recovery After Spinal Cord Injury
Plain-language title
Dalfampridine with nerve stimulation and exercise after spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06853015, who can take part
Record updated
3 June 2026